Advertisement

Journal of Zhejiang University SCIENCE B

, Volume 13, Issue 11, pp 948–954 | Cite as

Immunological effects of a 10-μg dose of domestic hepatitis B vaccine in adults

  • Jing-jing Ren
  • Xue-wei Dai
  • Zheng-gang Jiang
  • Ling-zhi Shen
  • Yong-di Chen
  • Qian Li
  • Wen Ren
  • Ying Liu
  • Jun Yao
  • Lan-juan Li
Communication

Abstract

Objective

To evaluate the immunological effects of three types of domestic 10-μg/dose hepatitis B vaccines in adults compared with a foreign vaccine, and to provide scientific evidence in support of adult hepatitis B vaccination.

Methods

Adults from five counties (Deqing, Changxing, Nanxun, Wuxing, Anji) in Huzhou City, Shaoxing County and Tongxiang County, Zhejiang Province, China were selected. Blood samples were taken to assess serum HBsAg, anti-HBs, and anti-HBc using a chemiluminescence immunoassay. Adults, aged 16 to 49 years and who were anti-HBs negative at baseline, received hepatitis B immunizations at 0, 1, and 6 months. Anti-HBs levels were assessed one month after the third and final vaccination.

Results

A total of 1 872 adults were immunized and the average positive rate was 89.5%. Four types of hepatitis B vaccine were used, including three from Chinese companies (Shenzhen Kangtai, Dalian High-Tech, and North China Pharmaceutical) and one from a UK company (GlaxoSmithKline). Their seroconversion rates were 81.67%, 95.05%, 89.64%, and 86.81%, respectively. There was a significant difference between the anti-HBs positive conversion rates of the four types (P<0.005) but the seroconversion rates among the different vaccines were not significantly different (χ 2=2.123, P=0.145). The average anti-HBs geometric mean titers (GMTs) of non-immune adults immunized with each of the four vaccines were 177.28, 473.23, 246.13, and 332.20 mIU/ml, respectively. There were no statistically significant differences in the GMTs between the three types of domestic vaccine and the foreign vaccine (t=−1.575, P=0.116).

Conclusions

Domestic recombinant hepatitis B vaccines can achieve immunization effects comparable to those of a foreign vaccine.

Key words

Hepatitis B Vaccines Immunization Geometric mean titer 

CLC number

R575.1 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bonanni, P., 1995. Implementation in Italy of a universal vaccination programme against hepatitis B. Vaccine, 13(s1):68–71. [doi:10.1016/0264-410X(95)80058-L]Google Scholar
  2. Bryan, J.P., Craig, P.G., Reyes, L., Hakre, S., Jaramillo, R., Harlan, H., MacArthy, P., Legters, L.J., 1995. Randomized comparison of 5 and 10 microgram doses of two recombinant hepatitis B vaccines. Vaccine, 13(11): 978–982. [doi:10.1016/0264-410X(95)00030-5]PubMedCrossRefGoogle Scholar
  3. Chang, M.H., Hadzic, D., Rouassant, S.H., Jonas, M., Kohn, I.J., Negro, F., Roberts, E., Sibal, A., 2004. Acute and chronic hepatitis: Working Group Report of the Second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr., 39(s2):584–588. [doi:10.1097/00005176-200406002-00002]CrossRefGoogle Scholar
  4. Coates, T., Wilson, R., Patrick, G., Andre, F., Watson, V., 2001. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin. Ther., 23(3):392–403. [doi:10.1016/S0149-2918(01)80044-8]PubMedCrossRefGoogle Scholar
  5. Daniels, D., Grytdal, S., Wasley, A., 2009. Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill. Summ., 58(3):1–27.PubMedGoogle Scholar
  6. Dong, M.H., Lin, Y.D., Qian, Y.H., Jiang, Y., Deng, Y., Ding, S., Ren, Y.J., 2009. Immunity effect of homemade recombinant yeast-derived hepatitis B vaccine in adults. Mod. Med. J. China, 11(2):24–26.Google Scholar
  7. Ganczak, M., Szych, Z., Korzen, M., 2009. Preoperative vaccination for HBV at Polish hospitals as a possible public health tool to limit the spread of the epidemic: a cross-sectional study. Vaccine, 27(30):3969–3974. [doi:10.1016/j.vaccine.2009.04.042]PubMedCrossRefGoogle Scholar
  8. Ganem, D., Prince, A.M., 2004. Hepatitis B virus infection—natural history and clinical consequences. N. Engl. J. Med., 350(11):1118–1129. [doi:10.1056/NEJMra031087]PubMedCrossRefGoogle Scholar
  9. Gilbert, C.L., Klopfer, S.O., Martin, J.C., Schodel, F.P., Bhuyan, P.K., 2011. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years. Hum. Vaccin, 7(12):1336–1342. [doi:10. 4161/hv.7.12.18333]PubMedCrossRefGoogle Scholar
  10. Goldstein, S.T., Zhou, F., Hadler, S.C., Bell, B.P., Mast, E.E., Margolis, H.S., 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol., 34(6):1329–1339. [doi:10.1093/ije/dyi206]PubMedCrossRefGoogle Scholar
  11. Gong, X.Y., Zhong, J.Y., 2009. Evaluation of Immunogenicity of 10 μg Recombinant yeast-derived hepatitis B vaccine in adults. China Prevent Med., 10(10):934–936 (in Chinese).Google Scholar
  12. Jilg, W., Schmidt, M., Deinhardt, F., 1988. Persistence of specific antibodies after hepatitis B vaccination. J. Hepatol., 6(2):201–207. [doi:10.1016/S0168-8278(88)80032-1]PubMedCrossRefGoogle Scholar
  13. Lavanchy, D., 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat., 11(2):97–107. [doi:10.1046/j.1365-2893.2003.00487.x]PubMedCrossRefGoogle Scholar
  14. Liang, X., Bi, S., Yang, W., Wang, L., Cui, G., Cui, F., Zhang, Y., Liu, J., Gong, X., Chen, Y., et al., 2009a. Epidemiological serosurvey of hepatitis B in China— declining HBV prevalence due to hepatitis B vaccination. Vaccine, 27(47):6550–6557. [doi:10.1016/j.vaccine.2009.08.048]PubMedCrossRefGoogle Scholar
  15. Liang, X., Bi, S., Yang, W., Wang, L., Cui, G., Cui, F., Zhang, Y., Liu, J., Gong, X., Chen, Y., et al., 2009b. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J. Infect. Dis., 200(1): 39–47. [doi:10.1086/599332]PubMedCrossRefGoogle Scholar
  16. Lu, F.M., Zhuang, H., 2009. Management of hepatitis B in China. Chin. Med. J. (Engl.), 122(1):3–4.Google Scholar
  17. Mast, E.E., Mahoney, F.J., Alter, M.J., Margolis, H.S., 1998. Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine, 16(Suppl.): 48–51. [doi:10.1016/S0264-410X(98)00294-1]CrossRefGoogle Scholar
  18. Mast, E.E., Weinbaum, C.M., Fiore, A.E., Alter, M.J., Bell, B.P., Finelli, L., Rodewald, L.E., Douglas, J.M.Jr., Janssen, R.S., Ward, J.W., 2006. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR Recomm. Rep., 55(RR-16):1–33, quiz CE31–CE34.PubMedGoogle Scholar
  19. Rendi-Wagner, P., Kundi, M., Stemberger, H., Wiedermann, G., Holzmann, H., Hofer, M., Wiesinger, K., Kollaritsch, H., 2001. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine, 19(15–16): 2055–2060. [doi:10.1016/S0264-410X(00)00410-2]PubMedCrossRefGoogle Scholar
  20. Shen, L.Z., Yao, J., 2011. Study development on booster immune strategy of hepatitis B vaccine. Zhejiang J. Prevent. Med., 23(12):22–25 (in Chinese).Google Scholar
  21. Trivello, R., Chiaramonte, M., Ngatchu, T., Baldo, V., Majori, S., Moschen, M.E., Simoncello, I., Renzulli, G., Naccarato, R., 1995. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine, 13(2):139–141. [doi:10.1016/0264-410X(95)93126-T]PubMedCrossRefGoogle Scholar
  22. Weinbaum, C.M., Williams, I., Mast, E.E., Wang, S.A., Finelli, L., Wasley, A., Neitzel, S.M., Ward, J.W., 2008. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep., 57(RR-8):1–20.PubMedGoogle Scholar
  23. WHO (World Health Organization), 2000. Hepatitis B. WHO, Geneva, Switzerland. Available from http://www.who.int/mediacentre/factsheets/fs204/en [Accessed on 2 June 2010].Google Scholar
  24. Yao, J., Chen, Y.D., 2009. Immunity effect of domestic hepatitis B vaccine in adults. China Prevent Med., 10(4): 258–261 (in Chinese).Google Scholar
  25. Yao, J., Ren, J.J., Shen, L.Z., Chen, Y.D., Liang, X.F., Cui, F.Q., Li, Q., Jiang, Z.G., Wang, F.Z., 2011. The effects of booster vaccination of hepatitis B vaccine on anti-HBV surface antigen negative children 11–15 years after primary vaccination. Hum. Vaccin., 7(10):1055–1059. [doi:10.4161/hv.7.10.15990]PubMedCrossRefGoogle Scholar
  26. Young, M.D., Gooch, W.M.3rd, Zuckerman, A.J., Du, W., Dickson, B., Maddrey, W.C., 2001. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination. J. Med. Virol., 64(3): 290–298. [doi:10.1002/jmv.1049]PubMedCrossRefGoogle Scholar
  27. Yuan, Y.B., Zheng, X.H., Wang, Z.Q., 2003. Study on the immuno-effects and security of Chinese Hamster Ovary (CHO) cell hepatitis B vaccine among adults, under different dosages. Chin. J. Infect. Dis., 21(6):423–424 (in Chinese).Google Scholar
  28. Zhang, W., Lin, C., Han, L., Li, L., Gao, P., Lin, H., Gong, X., Huang, F., Tang, Y., Ma, J., 2010. Study on the immuno-effects and influencing factors of Chinese Hamster Ovary (CHO) cell hepatitis B vaccine among adults, under different dosages. Chin. J. Epidemiol., 31(7): 767 (in Chinese).Google Scholar
  29. Zuckerman, J., Langer, B., 2005. Hepatitis B vaccination in a school age population: a feasibility study. J. Med. Virol., 76(1):47–54. [doi:10.1002/jmv.20335]PubMedCrossRefGoogle Scholar

Copyright information

© Zhejiang University and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Jing-jing Ren
    • 1
  • Xue-wei Dai
    • 2
  • Zheng-gang Jiang
    • 3
  • Ling-zhi Shen
    • 3
  • Yong-di Chen
    • 3
  • Qian Li
    • 3
  • Wen Ren
    • 4
  • Ying Liu
    • 4
  • Jun Yao
    • 2
  • Lan-juan Li
    • 1
  1. 1.State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Key Laboratory of Infectious Diseases, the First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
  2. 2.Department of Epidemiology and Statistics, School of MedicineNingbo UniversityNingboChina
  3. 3.Zhejiang Center for Disease Control and PreventionHangzhouChina
  4. 4.Department of Family Medicine, the First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations